Search
According to the latest Precedence Research report, the global biotechnology market size is expected to grow from $1.77 trillion in 2025 to $6.34 trillion by 2035, at a compound annual growth rate of 13.61%. AI-driven drug discovery, gene editing, and advanced biologics are becoming core growth engines.
The global clinical trial market size is expected to reach $143.46 billion by 2033, with AI and decentralized models reshaping the drug development landscape.
The life sciences industry is accelerating its transformation toward precision medicine and AI-driven R&D. This article analyzes the latest developments of companies such as GSK, Takeda, Vertex, Novartis, Dassault Systèmes, and BMS, exploring how strategic acquisitions, regulatory approvals, and AI infrastructure are jointly shaping the new landscape of global healthcare technology.
In 2026, the biotechnology sector is moving from promise to execution. AI-driven R&D, breakthroughs in gene editing, regulatory reforms, and global transactions are reshaping the life sciences landscape. This article examines 26 key trends, covering dimensions such as scientific innovation, emerging markets, policy changes, and business models.
In 2026, the biotech and life sciences industry reaches a critical turning point. From AI-driven drug discovery to clinical breakthroughs in gene editing, from regulatory reforms to global capital flows, these 26 trends are reshaping the future of medical innovation.
This article is based on Salesforce's latest industry insights, analyzing the core applications, industry trends, market impact, and potential challenges of AI in healthcare, and exploring the industrial path of medical AI evolving from an assistive tool to healthcare system infrastructure.
In 2026, the biotech and life sciences field reaches a critical turning point. AI and machine learning become R&D infrastructure, gene editing, synthetic biology, and microbiome therapies move toward clinical application, and global regulatory frameworks are being rapidly restructured. This article outlines 26 major trends, analyzing how technology, markets, capital, and policy are reshaping the healthcare innovation ecosystem.
Medical AI has moved from experimentation to clinical practice, but the practical application of diagnosis, treatment, and decision support still faces challenges in data, trust, and integration. This article reviews the current state and future trends.
This article analyzes the application of AI in the healthcare industry from an industrial perspective, focusing on how CRM platforms represented by Salesforce drive digital transformation in healthcare through AI agents, data integration, and patient relationship management, while also exploring development trends over the next 3-5 years.
Analyze how regulatory pressure, demand explosion, and drug repurposing are reshaping R&D investment strategies and the market landscape for biopharmaceutical companies.
Adcentrx Therapeutics announced that its ADC drug ADRX-0405 has received IND approval from China's NMPA and will be included in Chinese clinical centers to conduct global Phase 1a/1b trials targeting advanced solid tumors, especially prostate cancer. This article analyzes the significance of this technology to the medical industry, market impact, and future outlook.
Amgen is making additional investments in Puerto Rico to expand its biologics manufacturing network, while BioNTech is shutting down some factories in Germany and Singapore and cutting jobs. The different choices made by the two companies reflect how biopharmaceutical manufacturing is shifting from pandemic-driven expansion toward supply chain resilience, capacity efficiency, and a reconfiguration of pipeline priorities.
A recent Nature review points out that mRNA technology is moving from a vaccine tool toward a broader therapeutic platform. As bottlenecks around delivery, immune silencing, and tissue targeting are being addressed, the industry is entering the “mRNA therapeutics 2.0” phase.
GE HealthCare will showcase AI software, imaging systems, radiopharmaceuticals, and localized production solutions related to nuclear medicine during SNMMI 2026, reflecting that nuclear medicine is moving from competition among single devices toward a phase of expansion driven by “platformization + ecosystemization.”